J&J/Janssen win OK for Sylvant; 1st US drug in Castleman's
This article was originally published in Scrip
Johnson & Johnson subsidiary Janssen gained FDA approval on 23 April for Sylvant (siltuximab), the first drug in the US to treat patients with multicentric Castleman's disease (MCD), a rare blood disorder in which lymphocytes are over-produced, leading to enlarged lymph nodes, and which also can affect the lymphoid tissue of internal organs, causing the liver, spleen or other organs to enlarge.
You may also be interested in...
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
LEO Pharma is buying branded topical treatments worth more than €280m in annual sales from Bayer. Also, Apricus and Sellos agree to merge, Lilly partners on translation inhibitors with Anima, and Merck leverages Sutro's technology in cancer and autoimmune partnership.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.